Adalimumab with steroids for Behçet's eye inflammation
Part of Eyes & vision clinical trials.
This study tests a drug called adalimumab, which helps calm the immune system, when added to the steroid medicine you may already be taking. It aims to see if this combination is safe and works better for people with Behçet's disease that affects the back of the eye and has recently flared up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Behçet's disease and have had a recent flare of inflammation in the back part of your eye (uveitis).
- You are currently taking at least 10 mg of prednisone (a steroid) every day.
- You have not used a TNF inhibitor (like adalimumab or infliximab) in the last 3 months.
- You are not pregnant or breastfeeding, and you do not have cancer, heart failure, or certain other serious health conditions.
- Your kidney, liver, and blood counts are within acceptable ranges, and you do not have active infections like tuberculosis, hepatitis, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two forms of the same medicine (adalimumab) to treat non-infectious uveitis, an inflammation inside the eye. It aims to see which delivery method works better to control active inflammation and protect vision.
This trial tests whether people with chronic uveitis (eye inflammation) who have been stable on adalimumab (a biologic medicine) for at least 24 weeks can safely reduce their dose. The goal is to see if a lower dose can still control the inflammation while reducing side effects and costs.
This study tests a new drug (GenSci048) for people with active, non-infectious uveitis in the middle or back of the eye, who are already taking oral steroids. The goal is to see if the drug can better control inflammation and reduce the need for steroids.
This study compares two biologic medicines, adalimumab and tocilizumab, to see which works better for severe eye inflammation (uveitis) caused by Behçet's disease. Both are given as injections, and the goal is to improve vision and reduce eye damage.
This study tests a combination of two medicines, mycophenolate mofetil and adalimumab, to help control eye inflammation (uveitis) and reduce the need for steroids. It is for people who still have active inflammation despite taking a steroid medication like prednisone.
This study tests an injection called adalimumab (Tebiovio®) to see if it helps control inflammation in the eyes of adults with non-infectious uveitis. It might be a good option if you are already on steroid pills and looking for another treatment.
Hear when a new Uveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.